Viewing data from:

KARIVA

ANDA

DESOGESTREL; ETHINYL ESTRADIOL | A075863 | BARR LABORATORIES INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: CYCLESSA(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$0.1493

per ea

Lowest NADAC/Unit

$0.1493

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00555905058KARIVA 28 DAY TABLET	$0.1493	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

Medicare Part D Spending

CMS annual spending data for Kariva (2024)

Total Spending

$51K

Total Claims

1,296

Beneficiaries

399

Avg Cost/Unit

$0.57

Spending Trend

$132K(2019)→$124K(2020)→$83K(2021)→$63K(2022)→$52K(2023)→$51K(2024)

YoY Change:-18.5%

5yr CAGR:-15.9%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Apr 15, 2003	ORIG -1	View Letter (PDF)
Apr 10, 2003	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.15MG,N/A;0.02MG,0.01MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Apr 5, 2002

No patent or exclusivity listings for this strength.